Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
In: Journal of Clinical Oncology, Jg. 38 (2020-02-20), S. 684-684
Online
unknown
Zugriff:
684 Background: Immuno-Oncology (IO) combinations are standard of care first-line treatment for metastatic renal cell carcinoma (mRCC). Data on therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) post-progression on IO-combination therapy are limited. Methods: Using the IMDC, a retrospective analysis was done on mRCC patients treated with second-line VEGF TKIs after receiving IO combination therapy. Patients received first-line ipilimumab+nivolumab (IOIO) or anti-PD(L)1+anti-VEGF (IOVE). Baseline variables and second-line IMDC risk factors were collected. Overall response rates (ORR), time to treatment failure (TTF) and overall survival (OS) were determined. Multivariable Cox regression analysis was performed. Results: 142 patients were included. 75 patients received IOIO and 67 received IOVE pretreatment. The ORR of 2nd line therapy was 17/46 (37%) and 7/57 (12%) in the IOIO and IOVE pretreated groups, respectively (p
Titel: |
Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
|
---|---|
Autor/in / Beteiligte Person: | Kollmannsberger, Christian ; Chun Loo Gan ; Pal, Sumanta K. ; Powles, Thomas ; Hansen, Aaron R. ; Vaishampayan, Ulka N. ; Canil, Christina ; Bakouny, Ziad ; Wood, Lori ; Dizman, Nazli ; Wells, Connor ; Choueiri, Toni K. ; Donskov, Frede ; Basappa, Naveen S. ; Velasco, Guillermo ; Dudani, Shaan ; Beuselinck, Benoit ; Stukalin, Igor ; Daniel Y.C. Heng ; Agarwal, Neeraj |
Link: | |
Zeitschrift: | Journal of Clinical Oncology, Jg. 38 (2020-02-20), S. 684-684 |
Veröffentlichung: | American Society of Clinical Oncology (ASCO), 2020 |
Medientyp: | unknown |
ISSN: | 1527-7755 (print) ; 0732-183X (print) |
DOI: | 10.1200/jco.2020.38.6_suppl.684 |
Schlagwort: |
|
Sonstiges: |
|